الإحصائيات الأساسية
| CIK | 1584751 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Talis Biomedical Corporation
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| October 10, 2024 |
TLIS / Talis Biomedical Corporation / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SC 13D/A 1 tm2425930d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Talis Biomedical Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securi |
|
| September 30, 2024 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40047 Talis Biomedical Corporation (Exact name of registrant as s |
|
| September 17, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 (September 16, 2024) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction |
|
| September 17, 2024 |
LEASE TERMINATION AGREEMENT THIS LEASE TERMINATION AGREEMENT (this "Agreement") is entered into as of September 16, 2024 by and between FULTON OGDEN VENTURE, LLC, a Delaware limited liability company ("Landlord"), and TALIS BIOMEDICAL CORPORATION, a Delaware corporation ("Tenant"). |
|
| September 9, 2024 |
As filed with the Securities and Exchange Commission on September 9, 2024 As filed with the Securities and Exchange Commission on September 9, 2024 Registration No. |
|
| September 9, 2024 |
As filed with the Securities and Exchange Commission on September 9, 2024 As filed with the Securities and Exchange Commission on September 9, 2024 Registration No. |
|
| September 9, 2024 |
As filed with the Securities and Exchange Commission on September 9, 2024 As filed with the Securities and Exchange Commission on September 9, 2024 Registration No. |
|
| September 9, 2024 |
As filed with the Securities and Exchange Commission on September 9, 2024 As filed with the Securities and Exchange Commission on September 9, 2024 Registration No. |
|
| September 6, 2024 |
Exhibit 10.1 SETTLEMENT AGREEMENT This Settlement Agreement (the “Agreement”) is made and entered into effective as of August 29, 2024 (the “Effective Date”), by and among Talis Biomedical Corporation, a Delaware corporation (“Talis”), and Kriya Therapeutics, Inc., a Delaware corporation (“Kriya” and, together with Talis, the “Parties” and each, a “Party”). RECITALS WHEREAS, Talis, as subtenant, a |
|
| September 6, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 (August 30, 2024) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of I |
|
| September 5, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No.1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 (August 29, 2024) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Othe |
|
| September 3, 2024 |
EXHIBIT 10.1 PREPARED FOR SETTLEMENT PURPOSES ONLY SUBJECT TO FED. R. EVID. 408 In re Talis Biomedical Sec. Litig., No. 1:22-cv-00105-SI (N.D. Cal.) Settlement Term Sheet Lead Plaintiff and the Class ("Plaintiff''), on the one hand, and Defendants Tatis Biomedical Corporation ("Talis"), Brian Coe, J. Roger Moody, Jr., Felix Baker, Raymond Cheong, Melissa Gilliam, Rustem F. Ismagilov, Kimberly J. P |
|
| September 3, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 (August 29, 2024) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of I |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2024 (August 22, 2024) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Inc |
|
| August 19, 2024 |
EXHIBIT 10.6 Dear Rob: As you know, Talis Biomedical Corporation (the “Company”) is evaluating strategic alternatives, including the commencement of a bankruptcy case under chapter 11 of the U.S. Bankruptcy Code, and retention of our key employees is critical to this process. To assist with these changes, we are pleased to extend to you an offer to participate in the Company Retention Bonus Progra |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 46-3122255 (I. |
|
| August 19, 2024 |
EXHIBIT 10.7 Dear Becky: As you know, Talis Biomedical Corporation (the “Company”) is evaluating strategic alternatives, including the commencement of a bankruptcy case under chapter 11 of the U.S. Bankruptcy Code, and retention of our key employees is critical to this process. To assist with these changes, we are pleased to extend to you an offer to participate in the Company Retention Bonus Prog |
|
| August 19, 2024 |
Exhibit 10.3 April 10, 2024 Retention Agreement #2 Rebecca Markovich [Address redacted] [...]@gmail.com Dear Rebecca, We appreciate and value your contributions to Talis Bio. In an effort to incentivize you to maintain your at-will employment with us, we are pleased to offer you a one-time lump-sum retention bonus of $89,250.00 (gross), subject to the terms and conditions below. This retention bon |
|
| August 14, 2024 |
TLIS / Talis Biomedical Corporation / BML Investment Partners, L.P. Passive Investment SC 13G 1 tlis13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* Talis Biomedical Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87424L207 (CUSI |
|
| August 14, 2024 |
TLIS / Talis Biomedical Corporation / BML Investment Partners, L.P. Passive Investment SC 13G/A 1 tlis13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1 )* Talis Biomedical Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87424L207 |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ý Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on For |
|
| August 6, 2024 |
Director Services Agreement dated August 2, 2024 by and between the Company and Patricia Ferrari. August 2, 2024 Ms. Patricia K. Ferrari [Address redacted] Dear Ms. Ferrari: This Director Services Agreement (the “Agreement”) sets out the terms upon which you, Ms. Patricia K. Ferrari (“Director” or “you”), have agreed to act as an independent director on the board of directors (the “Board”) of Talis Biomedical Corporation, a Delaware corporation (the “Company”), with effect from the date that t |
|
| August 6, 2024 |
Director Services Agreement dated August 2, 2024 by and between the Company and John T. Young, Jr August 2, 2024 John T. Young, Jr. [Address redacted] Dear Mr. Young: This Director Services Agreement (the “Agreement”) sets out the terms upon which you, John T. Young, Jr. (“Director” or “you”), have agreed to act as an independent director on the board of directors (the “Board”) of Talis Biomedical Corporation, a Delaware corporation (the “Company”), with effect from the date that the Company’s |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 (July 31, 2024) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incor |
|
| August 6, 2024 |
Indemnification Agreement dated August 1, 2024 by and between the Company and Patricia Ferrari. INDEMNITY AGREEMENT This Indemnity Agreement (this “Agreement”) dated as of August 01, 2024, is made by and between Talis Biomedical Corporation, a Delaware corporation (the “Company”), and Patricia Ferrari (“Indemnitee”). |
|
| August 6, 2024 |
Indemnification Agreement dated August 1, 2024 by and between the Company and John T. Young, Jr INDEMNITY AGREEMENT This Indemnity Agreement (this “Agreement”) dated as of August 01, 2024 is made by and between Talis Biomedical Corporation, a Delaware corporation (the “Company”), and John T. |
|
| June 25, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 (June 24, 2024) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorpo |
|
| June 25, 2024 |
Exhibit 10.1 Amendment No. 3 to Waiver of Registration Rights This Amendment No. 3 to Waiver of Registration Rights (this “Amendment”) is entered into as of the date set forth on the signature page hereto between Talis Biomedical Corporation, a Delaware corporation (the “Company”), and the undersigned holders of shares of capital stock of the Company (the “Stockholders”). The parties entered into |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 (May 30, 2024) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorpora |
|
| June 3, 2024 |
Amendment No. 2 to Waiver of Registration Rights This Amendment No. 2 to Waiver of Registration Rights (this “Amendment”) is entered into as of the date set forth on the signature page hereto between Talis Biomedical Corporation, a Delaware corporation (the “Company”), and the undersigned holders of shares of capital stock of the Company (the “Stockholders”). The parties entered into that certain |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 46-3122255 (I. |
|
| May 8, 2024 |
Exhibit 10.3 April 10, 2024 Retention Agreement #2 Rebecca Markovich [Address redacted] [...]@gmail.com Dear Rebecca, We appreciate and value your contributions to Talis Bio. In an effort to incentivize you to maintain your at-will employment with us, we are pleased to offer you a one-time lump-sum retention bonus of $89,250.00 (gross), subject to the terms and conditions below. This retention bon |
|
| May 3, 2024 |
Amendment to Waiver of Registration Rights This Amendment to Waiver of Registration Rights (this “Amendment”) is entered into as of the date set forth on the signature page hereto between Talis Biomedical Corporation, a Delaware corporation (the “Company”), and the undersigned holders of shares of capital stock of the Company (the “Stockholders”). |
|
| May 3, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 (April 29, 2024) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorpor |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 (April 10, 2024) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incor |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40047 Talis Biomedic |
|
| March 28, 2024 |
WAIVER OF REGISTRATION RIGHTS This Waiver of Registration Rights is entered into as of March 25, 2024 by and between Talis Biomedical Corporation, a Delaware corporation (the “Company”), and the undersigned holders of shares of capital stock of the Company (the “Stockholders”). |
|
| March 28, 2024 |
Talis Biomedical Corporation Insider Trading Policy 2 February 2024 Policy Principles and Overview 1. |
|
| March 26, 2024 |
As filed with the Securities and Exchange Commission on March 26, 2024 As filed with the Securities and Exchange Commission on March 26, 2024 Registration No. |
|
| February 14, 2024 |
US87424L2079 / Talis Biomedical Corp. / GREENLIGHT CAPITAL INC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 sch13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Talis Biomedical Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87424L207 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statemen |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2024 (January 14, 2024) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of I |
|
| November 14, 2023 |
Exhibit 99.1 Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash REDWOOD CITY, Calif.– November 14, 2023 – Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 46-3122255 (I. |
|
| November 14, 2023 |
Exhibit 10.7 November 13, 2023 RebeccaMarkovich 3007 N Honore St Chicago, IL 60657 [...]@gmail.com Dear Rebecca, We appreciate and value your contributions to Talis Biomedical. In an effort to incentivize you to maintain your at-will employment with us, we are pleased to offer you a one-time lump-sum retention bonus of $59,500.00 (gross), subject to the terms and conditions below. This retention b |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 01, 2023 (August 30, 2023) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of |
|
| August 10, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Fees to be paid Equity Common Stock, par value $0. |
|
| August 10, 2023 |
As filed with the Securities and Exchange Commission on August 10, 2023 As filed with the Securities and Exchange Commission on August 10, 2023 Registration No. |
|
| August 10, 2023 |
Talis Biomedical Corporate Presentation August 2023 Decentralizing Women’s and Sexual Health Testing Exhibit 99. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 46-3122255 (I. |
|
| August 10, 2023 |
Exhibit 99.1 Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific REDWOOD CITY, Calif. – August 10, 2023 – Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of n |
|
| August 2, 2023 |
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO) Exhibit 99.1 Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO) REDWOOD CITY, Calif. – August 2, 2023 – Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that |
|
| August 2, 2023 |
Exhibit 10.1 JULY 27, 2023 Dear Andrew, It is with great enthusiasm that Talis Biomedical Corporation (“Talis” or the “Company”) is providing you an employment offer for the full-time position of President and Chief Scientific Officer, reporting to Robert Kelley, Chief Executive Officer. We are pleased to offer you a base salary at the rate of $450,000.00 per year, which will be paid in accordance |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2023 (July 28, 2023) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incor |
|
| July 27, 2023 |
Exhibit 99.1 New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu Preliminary data suggest a chlamydia, gonorrhea and trichomonas (CT/NG/TV) multiplex test is feasible on a molecular point-of-care (POC) test system with time to result in less than 30 minutes Ability to effec |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 (July 20, 2023) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorpo |
|
| July 24, 2023 |
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement REDWOOD CITY, Calif. – July 24, 2023 – Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it received written notice ( |
|
| July 5, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO The AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TALIS BIOMEDICAL CORPORATION Talis Biomedical Corporation (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: 1. The name of the Company is Talis Biomedical Corporation. The Company’s Cert |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 05, 2023 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 5, 2023 |
Talis Biomedical Announces 1-for-15 Reverse Stock Split Exhibit 99.1 Talis Biomedical Announces 1-for-15 Reverse Stock Split REDWOOD CITY, Calif. – July 5, 2023 – Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will effect a 1-for-15 reverse stock split of th |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09, 2023 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 (May 19, 2023) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorpora |
|
| May 23, 2023 |
Exhibit 99.1 Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director REDWOOD CITY, Calif. – May 23, 2023 – Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 11, 2023 |
Exhibit 99.1 Talis Biomedical Announces Business Update and First Quarter 2023 Financial Results Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific REDWOOD CITY, Calif. – May 11, 2023 – Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 46-3122255 (I. |
|
| May 11, 2023 |
Talis Biomedical Corporate Presentation May 2023 Decentralizing Women’s and Sexual Health Testing Talis Biomedical Corporate Presentation May 2023 Decentralizing Women’s and Sexual Health Testing Disclaimer This presentation may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. |
|
| May 8, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023(May 04, 2023) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporat |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 (April 7, 2023) Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorp |
|
| March 22, 2023 |
Talis Announces Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Talis Announces Fourth Quarter and Full Year 2022 Financial Results REDWOOD CITY, Calif. – March 22, 2023 – Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the fourth quarter an |
|
| March 22, 2023 |
Exhibit 10.19 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUBLEASE 1100 Island Drive, Suite 101, Redwood City, CA 94065 This Sublease (“Sublease”), dated March 16, 2023 ( “Execution Date”), is entered into |
|
| March 22, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 22, 2023 |
Exhibit 10.18 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LEASE TERMINATION AGREEMENT This Lease Termination Agreement (the “Agreement”) dated as of March 16, 2023 (“Effective Date”), is executed by and bet |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40047 Talis Biomedic |
|
| March 22, 2023 |
Exhibit 10.21 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. TERMINATON AND RELEASE AGREEMENT THIS TERMINATION AND RELEASE AGREEMENT (the “Agreement”) is made effective as of March 21, 2023 (the “Effective Dat |
|
| March 22, 2023 |
Exhibit 10.22 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ATTACHMENT 1 TO THE TERMINATION AGREEMENT License Agreement This License Agreement (“License Agreement”) is entered into as of March 22, 2023 (the “ |
|
| March 22, 2023 |
EX-10 4 tlis-ex1020.htm EX-10.20 Exhibit 10.20 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONSENT TO SUBLEASE This Consent to Sublease (the "Consent") is entered into as of March 16, 2023 (“Effective Date” |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 10, 2023 |
TLIS / Talis Biomedical Corp / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| February 15, 2023 |
TLIS / Talis Biomedical Corporation / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
TLIS / Talis Biomedical Corporation / GREENLIGHT CAPITAL INC Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Talis Biomedical Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87424L108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| January 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 3, 2022 |
Talis Biomedical Reports Third Quarter 2022 Financial Results Exhibit 99.1 Talis Biomedical Reports Third Quarter 2022 Financial Results REDWOOD CITY, Calif. – November 3, 2022 – Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the third quarter ended S |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 46-3122255 (I. |
|
| September 12, 2022 |
TLIS / Talis Biomedical Corporation / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 2, 2022 |
Exhibit 99.1 Talis Biomedical Provides Business Update and Reports Second Quarter Financial Results Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific REDWOOD CITY, Calif. – August 2, 2022 – Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at th |
|
| August 2, 2022 |
Calculation of Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 Talis Biomedical Corporation Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| August 2, 2022 |
Exhibit 10.2 Talis Biomedical Corporation 2021 Employee Stock Purchase Plan Adopted by the Board of Directors: February 5, 2021 Approved by the Stockholders: February 5, 2021 IPO Date: February 11, 2021 Amendment Adopted by the Board of Directors: March 7, 2022 Amendment Adopted by the Stockholders: June 10, 2022 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the |
|
| August 2, 2022 |
Exhibit 10.1 Talis Biomedical Corporation 2021 Equity Incentive Plan Adopted by the Board of Directors: February 5, 2021 Approved by the Stockholders: February 5, 2021 IPO Date: February 11, 2021 Amendment Adopted by the Board of Directors: March 7, 2022 Amendment Adopted by the Stockholders: June 10, 2022 Table of Contents Page 1. General. 1 2. Shares Subject to the Plan. 1 3. Eligibility and Lim |
|
| August 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2022 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 2, 2022 |
Exhibit 10.3 Talis Biomedical Corporation Non-Employee Director Compensation Policy Effective Date: February 11, 2021 Amended and Restated: May 25, 2022 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Talis Biomedical Corporation (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation describe |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 46-3122255 (I. |
|
| August 2, 2022 |
As filed with the Securities and Exchange Commission on August 2, 2022 As filed with the Securities and Exchange Commission on August 2, 2022 Registration No. |
|
| June 13, 2022 |
TLIS / Talis Biomedical Corporation / BAKER BROS. ADVISORS LP - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2022 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2022 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 24, 2022 |
PROSPECTUS 37,489,210 shares of Common Stock Offered by the Selling Stockholder Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-264839 PROSPECTUS 37,489,210 shares of Common Stock Offered by the Selling Stockholder This prospectus covers the offer and resale by the selling stockholder identified in this prospectus of up to an aggregate of 37,489,210 shares of our common stock, which includes 29,863,674 shares of common stock issuable upon the conversio |
|
| May 20, 2022 |
Talis Biomedical Corporation 230 Constitution Drive Menlo Park, California 94025 CORRESP 1 filename1.htm Talis Biomedical Corporation 230 Constitution Drive Menlo Park, California 94025 May 20, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Michael Davis and Laura Crotty RE: Talis Biomedical Corporation Registration Statement on Form S-3 File No. 333-264839 Acceleration Request Requested Da |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 46-3122255 (I. |
|
| May 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Share(3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| May 10, 2022 |
Exhibit 99.1 Talis Biomedical Announces First Quarter 2022 Financial Results Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific MENLO PARK, Calif. ? May 10, 2022 ? Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today repo |
|
| May 10, 2022 |
As filed with the Securities and Exchange Commission on May 10, 2022 Table of Contents As filed with the Securities and Exchange Commission on May 10, 2022 Registration No. |
|
| April 26, 2022 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ? 240. |
|
| April 26, 2022 |
DEFA14A 1 tlisdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 22, 2022 |
TALIS BIOMEDICAL CORPORATION 230 Constitution Drive Menlo Park, California 94025 TALIS BIOMEDICAL CORPORATION 230 Constitution Drive Menlo Park, California 94025 April 22, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2021 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 16, 2022 |
As filed with the Securities and Exchange Commission on March 15, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. |
|
| March 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Share(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| March 15, 2022 |
Exhibit 99.1 Talis Biomedical Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific MENLO PARK, Calif. ? March 15, 2022 ? Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the mome |
|
| March 15, 2022 |
Exhibit 10.8 Talis Biomedical Corporation Severance and Change in Control Plan a. Introduction. The Talis Biomedical Corporation Severance and Change in Control Plan (the ?Plan?) is hereby established by the Board of Directors of Talis Biomedical Corporation (the ?Company?) effective upon the IPO Date (as defined below). The purpose of the Plan is to provide for the payment of severance and/or Cha |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 Talis Biomedical Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-40047 46-3122255 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 15, 2022 |
Exhibit 10.17 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Exhibit A-1 This Exhibit A-1 Replaces Exhibit A to the Supply Agreement dated May 22, 2020 between Thinxxs Microtechnology AG And TALIS BIOMEDICAL C |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40047 Talis Biomedic |
|
| March 15, 2022 |
Talis Biomedical Corporation Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.7 Talis Biomedical Corporation Non-Employee Director Compensation Policy Effective Date: February 11, 2021 Amended and Restated: December 17, 2021 Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Talis Biomedical Corporation (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the |
|
| February 14, 2022 |
TLIS / Talis Biomedical Corporation / GREENLIGHT CAPITAL INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Talis Biomedical Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87424L108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 14, 2022 |
TLIS / Talis Biomedical Corporation / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
TLIS / Talis Biomedical Corporation / Boxer Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TALIS BIOMEDICAL CORPORATION (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 87424L108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 14, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G and/or 13D (including any and all amendments thereto) with respect to Common Stock, par value $0.0001 per share, of Talis Biomedical Corporation, and further agree that this Joi |
|
| December 9, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 Talis Biomedical Corporation (Exact name of registrant as specified in its charter) Delaware 001-40047 46-3122255 (State or other jurisdiction of incorporation or org |
|
| December 9, 2021 |
Exhibit 10.1 8 DECEMBER 2021 Dear Robert, It is with great enthusiasm that Talis Biomedical Corporation (?Talis? or the ?Company?) is providing you an offer for continued employment in the full-time position of Chief Executive Officer, reporting to the Company?s Board of Directors (the ?Board?), under the terms of this offer letter agreement (the ?Agreement?), and effective as of the date you have |
|
| November 22, 2021 |
As filed with the Securities and Exchange Commission on November 22, 2021 As filed with the Securities and Exchange Commission on November 22, 2021 Registration No. |
|
| November 16, 2021 |
Exhibit 10.2 Talis Biomedical Corporation RSU Award Grant Notice (2021 Equity Incentive Plan) Talis Biomedical Corporation (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in t |
|
| November 16, 2021 |
Exhibit 10.1 Talis Biomedical Corporation August 28, 2021 Brian Coe Re:Separation and Consulting Agreement Dear Brian: This letter sets forth the substance of the separation and consulting agreement (the ?Agreement?) that Talis Biomedical Corporation (the ?Company?) is offering to you to aid in your employment transition. 1. RESIGNATION DATES. (a)Employment Termination. Your last day of work with |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number: 001-40047 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR ? For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form. |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 46-3122255 (I. |
|
| November 15, 2021 |
Exhibit 10.4 Standard Form Talis Biomedical Corporation RSU Award Grant Notice (2021 Inducement Plan) Talis Biomedical Corporation (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company?s 2021 Induceme |
|
| November 15, 2021 |
Offer Letter, dated November 1, 2021, by and between the Company and Brian Blaser. Exhibit 10.1 MONDAY, NOVEMBER 1, 2021 Dear Brian, It is with great enthusiasm that Talis Biomedical Corporation (?Talis? or the ?Company?) is providing you an employment offer for the full-time position of Chief Executive Officer, reporting to the Company?s Board of Directors (the ?Board?). In addition, you will be appointed to the Board following the date you commence employment with the Company. |
|
| November 15, 2021 |
Exhibit 99.2 Talis Biomedical Announces Appointment of Brian Blaser as President, Chief Executive Officer and Director Veteran executive previously led Abbott's global diagnostics organization Kim Popovits, interim chief executive officer, to resume role as Director on the Board of Talis MENLO PARK, Calif. ? November 15, 2021 ? Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to ad |
|
| November 15, 2021 |
Exhibit 99.1 Talis Biomedical Announces Third Quarter 2021 Financial Results and Business Progress Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific MENLO PARK, Calif. ? November 15, 2021 ? Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at th |
|
| November 15, 2021 |
Exhibit 10.2 Talis Biomedical Corporation 2021 Inducement Plan Adopted by the Board of Directors: November 11, 2021 Table of Contents Page 1. General.1 2. Shares Subject to the Plan.1 3. Eligibility and Limitations.2 4. Options and Stock Appreciation Rights.2 5. Awards Other Than Options and Stock Appreciation Rights.6 6. Adjustments upon Changes in Common Stock; Other Corporate Events.8 7. Admini |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 Talis Biomedical Corporation (Exact name of registrant as specified in its charter) Delaware 001-40047 46-3122255 (State or other jurisdiction of incorporation or org |
|
| November 15, 2021 |
Exhibit 10.3 Standard Form Talis Biomedical Corporation Stock Option Grant Notice (2021 Inducement Plan) Talis Biomedical Corporation (the ?Company?), pursuant to its 2021 Inducement Plan (the ?Plan?), has granted to you (?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as set fo |
|
| November 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Talis Biomedical Corporation (Exact name of registrant as specified in its charter) Delaware 001-40047 46-3122255 (State or other jurisdiction of incorporation or or |
|
| November 10, 2021 |
EX-99.1 2 tlis-ex9916.htm EX-99.1 Exhibit 99.1 Talis Biomedical Granted FDA Emergency Use Authorization (EUA) for COVID-19 Molecular Point-of-Care Test to Detect SARS-CoV-2 Authorized for use in a variety of healthcare and congregate settings, Talis One™ enables lab-quality results without the wait to detect or rule out COVID-19 in less than 30 minutes Talis One’s robust dual gene target design op |
|
| August 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2021 Talis Biomedical Corporation (Exact name of registrant as specified in its charter) Delaware 001-40047 46-3122255 (State or other jurisdiction of incorporation or orga |
|
| August 31, 2021 |
Talis Biomedical Announces CEO Transition Kim Popovits to serve as interim CEO Exhibit 99.1 Talis Biomedical Announces CEO Transition Kim Popovits to serve as interim CEO MENLO PARK, Calif. ? August 30, 2021 ? Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that effective immediately Brian Coe has stepped down as President, CEO and Director and w |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Talis Biomedical Corporation (Exact name of registrant as specified in its charter) Delaware 001-40047 46-3122255 (State or other jurisdiction of incorporation or orga |
|
| August 10, 2021 |
Exhibit 99.1 Talis Biomedical Announces Second Quarter 2021 Financial Results and Business Progress Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific MENLO PARK, Calif. ? August 10, 2021 ? Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today reported financial result |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 46-3122255 (I. |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 46-3122255 (I. |
|
| May 13, 2021 |
Exhibit 10.1 LEASE 3565 Haven Avenue Menlo Park, California Basic Lease Information Date: April 7, 2021 Landlord: SFF 3565 HAVEN, LLC, a California limited liability company Tenant: TALIS BIOMEDICAL CORPORATION, a Delaware corporation Building (section 1.1): That certain building located at 3565 Haven Avenue, Menlo Park, California Premises (section 1.1): Approximately 5,278 rentable square feet o |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 Talis Biomedical Corporation (Exact name of registrant as specified in its charter) Delaware 001-40047 46-3122255 (State or other jurisdiction of incorporation or organiz |
|
| May 11, 2021 |
EX-99.1 2 tlis-ex9916.htm EX-99.1 Exhibit 99.1 Talis Biomedical Announces First Quarter 2021 Financial Results and Business Progress Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific MENLO PARK, Calif. – May 11, 2021 – Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, t |
|
| April 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| March 30, 2021 |
Exhibit 4.5 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made as of March 26, 2021 by and between Talis Biomedical Corporation, a Delaware corporation (the ?Company?), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the ?Investors?). Unless otherwise defined herein, capitalized terms used in this Agree |
|
| March 30, 2021 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Talis Biomedical Corporation (we, our or us) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following summary does not purport to be complete and is based on the provisions of our amended and res |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40047 Talis Biomedic |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2021 Talis Biomedical Corporation (Exact name of registrant as specified in its charter) Delaware 001-40047 46-3122255 (State or other jurisdiction of incorporation or organ |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 Talis Biomedical Corporation (Exact name of registrant as specified in its charter) Delaware 001-40047 46-3122255 (State or other jurisdiction of incorporation or organi |
|
| March 8, 2021 |
EX-99.1 Exhibit 99.1 Talis Provides Update on Regulatory Pathway for Emergency Use Authorization (EUA) of its Talis One™ COVID-19 Test MENLO PARK, Calif. – March 8, 2021 – Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it has withdrawn its current application pur |
|
| February 26, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Talis Biomedical Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 87424L108 (CUSIP Number) February 17, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 26, 2021 |
Exhibit 99.3 LOCK-UP AGREEMENT October 15, 2020 J.P. MORGAN SECURITIES LLC BOFA SECURITIES, INC. As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o BofA Securities, Inc. One Bryant Park New York, NY 10036 Re: Talis Biomedical Corporation — Initial Public Offerin |
|
| February 26, 2021 |
EX-99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the common stock of Talis Biomedical Corporation, $0.0001 par value per share, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| February 26, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D (and any amendments thereto) need be filed with respect to the beneficial ownership by each of the undersigned of securities of Talis Biomedical Corporation. This Agreement ma |
|
| February 17, 2021 |
Exhibit 99.2 TALIS BIOMEDICAL CORPORATION 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 5, 2021 APPROVED BY THE STOCKHOLDERS: FEBRUARY 5, 2021 IPO DATE: FEBRUARY 11, 2021 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 7 |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 Talis Biomedical Corporation (Exact name of registrant as specified in its charter) Delaware 001-40047 46-3211155 (State or other jurisdiction of incorporation or or |
|
| February 17, 2021 |
As filed with the Securities and Exchange Commission on February 17, 2021 Registration No. |
|
| February 17, 2021 |
EX-3.1 2 d134790dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TALIS BIOMEDICAL CORPORATION Brian Coe hereby certifies that: ONE: The original name of this company is SlipChip Corporation and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was June 26, 2013. TWO: He is the duly |
|
| February 17, 2021 |
Exhibit 99.3 TALIS BIOMEDICAL CORPORATION 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 5, 2021 APPROVED BY THE STOCKHOLDERS: FEBRUARY 5, 2021 IPO DATE: FEBRUARY 11, 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common St |
|
| February 17, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF TALIS BIOMEDICAL CORPORATION ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corpora |
|
| February 12, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-252360 and 333-253019 Prospectus 13,800,000 shares Common stock This is the initial public offering of shares of common stock of Talis Biomedical Corporation. We are offering 13,800,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price o |
|
| February 11, 2021 |
S-1MEF As filed with the U.S. Securities and Exchange Commission on February 11, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TALIS BIOMEDICAL CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 3826 46-3122255 (State or Other Jurisdiction of Incorporation |
|
| February 11, 2021 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 11, 2021. |
|
| February 9, 2021 |
February 9, 2021 (File No. 001-40047) 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Talis Biomedical Corporation (Exact name of registrant as specified in its charter) Delaware 46-3211155 (State of incorporation or organization) (I. |
|
| February 9, 2021 |
TALIS BIOMEDICAL CORPORATION 230 Constitution Drive Menlo Park, California 94025 February 9, 2021 VIA EDGAR U. |
|
| February 9, 2021 |
J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 BofA Securities, Inc. One Bryant Park New York, NY 10036 February 9, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Gabor, Tim Buchmiller, Michael Fay, and Brian Cascio Re: Talis Biomedical Corporation Request for Accelerati |
|
| February 8, 2021 |
EX-10.15 Exhibit 10.15 LEASE LANDLORD: FULTON OGDEN VENTURE, LLC, A Delaware limited liability company TENANT: TALIS BIOMEDICAL CORPORATION, a Delaware corporation Regarding the Premises Located at: Suite 700 West End on Fulton 1375 West Fulton Market Chicago, Illinois TABLE OF CONTENTS Section Page 1. BASIC LEASE TERMS 1 2. DEMISE AND USE 4 3. LETTER OF CREDIT 8 4. BASE RENT AND OPERATING EXPENSE |
|
| February 8, 2021 |
Talis Biomedical Corporation 2021 Employee Stock Purchase Plan. EX-10.4 Exhibit 10.4 TALIS BIOMEDICAL CORPORATION 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: [], 2021 APPROVED BY THE STOCKHOLDERS: [], 2021 IPO DATE: [], 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan per |
|
| February 8, 2021 |
Amended and Restated Certificate of Incorporation, as amended, as currently in effect. EX-3.1 Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TALIS BIOMEDICAL CORPORATION Brian Coe hereby certifies that: ONE: The original name of this company is SlipChip Corporation and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was June 26, 2013. TWO: He is the duly elected and acting |
|
| February 8, 2021 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 8, 2021. |
|
| February 8, 2021 |
Talis Biomedical Corporation Severance and Change in Control Plan. Exhibit 10.6 TALIS BIOMEDICAL CORPORATION SEVERANCE AND CHANGE IN CONTROL PLAN Section 1. INTRODUCTION. The Talis Biomedical Corporation Severance and Change in Control Plan (the “Plan”) is hereby established by the Board of Directors of Talis Biomedical Corporation (the “Company”) effective upon the IPO Date (as defined below). The purpose of the Plan is to provide for the payment of severance an |
|
| February 8, 2021 |
Form of Amended and Restated Bylaws to become effective upon the completion of this offering. EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF TALIS BIOMEDICAL CORPORATION ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the |
|
| February 8, 2021 |
Talis Biomedical Corporation Non-Employee Director Compensation Policy. Exhibit 10.5 TALIS BIOMEDICAL CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Talis Biomedical Corporation (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy |
|
| February 8, 2021 |
EX-4.1 Exhibit 4.1 NUMBER SHARES COUNTERSIGNED: BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC. TRANSFER AGENT BY: AUTHORIZED SIGNATURE DATED: INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP SEE REVERSE FOR CERTAIN DEFINITIONS This Certifies That: is the owner of C O M M ON S T O C K CHIEF FINANCIAL OFFICER CHIEF EXECUTIVE OFFICER FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF $0.0 |
|
| February 8, 2021 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 TALIS BIOMEDICAL CORPORATION [●] Shares of Common Stock Underwriting Agreement [●], 2021 J.P. Morgan Securities LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o BofA Securities, Inc. One Bryant Park New York, NY 10036 Ladies and Gentlemen: Talis Biomedical |
|
| February 8, 2021 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TALIS BIOMEDICAL CORPORATION Brian Coe hereby certifies that: ONE: The original name of this company is SlipChip Corporation and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was June 26, 2013. TWO: He is the duly elected and acting Chief E |
|
| February 8, 2021 |
Karen E. Deschaine +1 858 550 6088 [email protected] VIA EDGAR February 8, 2021 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Gabor, Tim Buchmiller, Michael Fay, and Brian Cascio Re: Talis Biomedical Corporation Registration Statement on Form S-1 Filed January 22, 2021 File No. 333-252360 |
|
| February 8, 2021 |
EX-10.3 Exhibit 10.3 TALIS BIOMEDICAL CORPORATION 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: [], 2021 APPROVED BY THE STOCKHOLDERS: [], 2021 IPO DATE: [], 2021 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 7 6. ADJUSTMENTS U |
|
| February 8, 2021 |
EX-10.16 Exhibit 10.16 LEASE AGREEMENT By and Between WESTPORT OFFICE PARK, LLC, a Delaware limited liability company (“Landlord”) and TALIS BIOMEDICAL CORPORATION, a Delaware corporation (“Tenant”) January 20, 2021 TABLE OF CONTENTS Page ARTICLE 1. PREMISES; COMMON AREAS 4 ARTICLE 2. TERM AND CONDITION OF PREMISES 5 ARTICLE 3. USE, NUISANCE, OR HAZARD 8 ARTICLE 4. RENT 9 ARTICLE 5. RENT ADJUSTMEN |
|
| January 22, 2021 |
Karen E. Deschaine +1 858 550 6088 [email protected] VIA EDGAR January 22, 2021 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Gabor, Tim Buchmiller, Michael Fay, and Brian Cascio Re: Talis Biomedical Corporation Draft Registration Statement on Form S-1 and Amendment No. 1 thereto Submitted |
|
| January 22, 2021 |
EX-4.2 Exhibit 4.2 TALIS BIOMEDICAL CORPORATION AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 30th day of October, 2020, by and among TALIS BIOMEDICAL CORPORATION, a Delaware corporation (the “Company”) and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each in |
|
| January 22, 2021 |
Amended and Restated Certificate of Incorporation, as amended, as currently in effect. EX-3.1 Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TALIS BIOMEDICAL CORPORATION Brian Coe hereby certifies that: ONE: The original name of this company is SlipChip Corporation and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was June 26, 2013. TWO: He is the duly elected and acting |
|
| January 22, 2021 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on January 22, 2021. |
|
| January 22, 2021 |
Contract, dated July 30, 2020, by and between the Registrant and the National Institutes of Health. EX-10.14 Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1 I 35 2. AM ENDMENT/M CODIFICATION NO . 3. EFFECTIVE DATE 4 REQUISITE ION/PU RCHASE REO NO. 15. PROJECT NO. (/I applicable) P00 001 |
|
| January 22, 2021 |
EX-10.12 Exhibit 10.12 TENANT: SLIPCHIP CORPORATION LEASE TABLE OF CONTENTS ARTICLE TITLE PAGE ARTICLE 1 - PREMISES AND TERM 1 ARTICLE 2 - RENT 2 ARTICLE 3 - LANDLORD’S WORK - TENANT’S WORK 3 ARTICLE 4 - STREETS 5 ARTICLE 5 - UTILITY SERVICES 5 ARTICLE 6 - ASSIGNMENT - CHANGE OF OWNERSHIP 5 ARTICLE 7 - TENANT’S ADDITIONAL AGREEMENTS 8 ARTICLE 8 - USE OF PREMISES 12 ARTICLE 9 - INDEMNITY AND PUBLIC |
|
| January 22, 2021 |
EX-10.10 Exhibit 10.10 MONDAY, SEPTEMBER 21, 2020 Dear Doug, It is with great enthusiasm that Talis Biomedical Corporation is providing you an employment offer for the full-time position of SVP, Operations, reporting to Brian Coe, Chief Executive Officer. We are pleased to offer you a base salary of $325,000.00 per year which is paid on a semi-monthly basis. The target annual bonus for this positi |
|
| January 22, 2021 |
EX-4.3 Exhibit 4.3 NOMINATING AGREEMENT THIS NOMINATING AGREEMENT (this “Agreement”), dated as of November 1, 2019, by and among Talis Biomedical Corporation, a Delaware corporation (the “Company”), Baker Brothers Life Sciences, L.P. (“BBLS”) and 667, L.P. (together with BBLS, the “Investor”). WHEREAS, the Company and the Investor are parties to that certain Series C-1 Preferred Stock and Series D |
|
| January 22, 2021 |
Offer Letter, dated December 1, 2014, by and between the Registrant and Karen E. Flick. EX-10.8 Exhibit 10.8 SlipChip Corporation 118 N. Clinton Street, Suite 205 Chicago, IL 60661 December 1, 2014 Karen Flick, Ph.D., J.D. Dear Karen, It is with great enthusiasm that I offer you the position of IP Counsel of SlipChip Corporation (the “Company”) reporting to the Chief Executive Officer. In this position, you will be expected to lead all elements related to creating and maintaining the |
|
| January 22, 2021 |
EX-10.9 Exhibit 10.9 WEDNESDAY, AUGUST 19, 2020 Dear Robert, It is with great enthusiasm that Talis Biomedical Corporation is providing you an employment offer for the full-time position of Chief Commercial Officer, reporting to Brian Coe, Chief Executive Officer. We are pleased to offer you a base salary of $300,000.00 per year which is paid on a semi-monthly basis. The target annual bonus for th |
|
| January 22, 2021 |
EX-10.7 Exhibit 10.7 FRIDAY, APRIL 3, 2020 Dear Roger, It is with great enthusiasm that Talis Biomedical Corporation is providing you an employment offer for the full-time position of Chief Financial Officer, reporting to Brian Coe, Chief Executive Officer. We are pleased to offer you a base salary of $360,000.00 per year which is paid on a semi-monthly basis. The target annual bonus for this posi |
|
| January 22, 2021 |
Offer Letter, dated April 23, 2019, by and between the Registrant and Ramesh Ramakrishnan. EX-10.11 Exhibit 10.11 TUESDAY, APRIL 23, 2019 Dear Ramesh, It is with great enthusiasm that Talis Biomedical Corp is providing you an employment offer for the full-time position of SVP, R&D, reporting to Brian Coe, Co-Founder and CEO. We are pleased to offer you a base salary of $285,000.00 per year which is paid on a semi- monthly basis. The target annual bonus for this position is 30% Your sala |
|
| January 22, 2021 |
EX-10.13 Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (the “Agreement”) is entered into as of 22 May 2020 (the “Effective Date”), by and between and thinXXS Microtechnology AG, a German corporation |
|
| January 22, 2021 |
Bylaws, as currently in effect. EX-3.3 Exhibit 3.3 BYLAWS OF TALIS BIOMEDICAL CORPORATION (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by |
|
| January 22, 2021 |
EX-10.2 Exhibit 10.2 TALIS BIOMEDICAL CORPORATION 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 27, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 27, 2013 AMENDED BY THE BOARD OF DIRECTORS: JULY 12, 2013 AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 18, 2015 APPROVED BY THE STOCKHOLDERS: FEBRUARY 19, 2015 AMENDED BY THE BOARD OF DIRECTORS: OCTOBER 5, 2017 AMENDED BY THE BOARD OF DIREC |
|
| January 22, 2021 |
EX-10.1 Exhibit 10.1 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between TALIS BIOMEDICAL CORPORATION, a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company’s Amended and Restated |
|
| January 6, 2021 |
SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TALIS BIOMEDICAL CORPORATION Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TALIS BIOMEDICAL CORPORATION Brian Coe hereby certifies that: ONE: The original name of this company is SlipChip Corporation and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was June 26, 2013. TWO: He is the duly elected and acting Chief |
|
| January 6, 2021 |
TALIS BIOMEDICAL CORPORATION AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT EX-4.2 4 filename4.htm Exhibit 4.2 TALIS BIOMEDICAL CORPORATION AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 30th day of October, 2020, by and among TALIS BIOMEDICAL CORPORATION, a Delaware corporation (the “Company”) and the investors listed on Exhibit A hereto, referred to hereinafter as the “Invest |
|
| January 6, 2021 |
BYLAWS TALIS BIOMEDICAL CORPORATION (A DELAWARE CORPORATION) ARTICLE I EX-3.3 3 filename3.htm Exhibit 3.3 BYLAWS OF TALIS BIOMEDICAL CORPORATION (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as |
|
| January 6, 2021 |
EX-10.14 5 filename5.htm Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1 I 35 2. AM ENDMENT/M CODIFICATION NO . 3. EFFECTIVE DATE 4 REQUISITE ION/PU RCHASE REO NO. 15. PROJECT NO. (/I app |
|
| January 6, 2021 |
Table of Contents As submitted confidentially to the Securities and Exchange Commission on January 5, 2021. |
|
| January 5, 2021 |
Karen E. Deschaine +1 858 550 6088 [email protected] VIA EDGAR January 5, 2021 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Gabor, Tim Buchmiller, Michael Fay, and Lisa Vanjoske Re: Talis Biomedical Corporation Draft Registration Statement on Form S-1 Submitted October 15, 2020 CIK No. 00 |
|
| October 15, 2020 |
EX-10.14 4 filename4.htm Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (the “Agreement”) is entered into as of 22 May 2020 (the “Effective Date”), by and between and thinXXS Microtechnology AG, a Ger |
|
| October 15, 2020 |
EX-4.3 2 filename2.htm Exhibit 4.3 NOMINATING AGREEMENT THIS NOMINATING AGREEMENT (this “Agreement”), dated as of November 1, 2019, by and among Talis Biomedical Corporation, a Delaware corporation (the “Company”), Baker Brothers Life Sciences, L.P. (“BBLS”) and 667, L.P. (together with BBLS, the “Investor”). WHEREAS, the Company and the Investor are parties to that certain Series C-1 Preferred St |
|
| October 15, 2020 |
EX-10.13 3 filename3.htm Exhibit 10.13 TENANT: SLIPCHIP CORPORATION LEASE TABLE OF CONTENTS ARTICLE TITLE PAGE ARTICLE 1 - PREMISES AND TERM 1 ARTICLE 2 - RENT 2 ARTICLE 3 - LANDLORD’S WORK - TENANT’S WORK 3 ARTICLE 4 - STREETS 5 ARTICLE 5 - UTILITY SERVICES 5 ARTICLE 6 - ASSIGNMENT - CHANGE OF OWNERSHIP 5 ARTICLE 7 - TENANT’S ADDITIONAL AGREEMENTS 8 ARTICLE 8 - USE OF PREMISES 12 ARTICLE 9 - INDE |
|
| October 15, 2020 |
Table of Contents As submitted confidentially to the Securities and Exchange Commission on October 15, 2020. |
